PRINCETON, N.J. --(BUSINESS WIRE)--Dec. 2, 2024-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that new data on UGN-102 (mitomycin) for intravesical solution,
The Study Results are Published in the Journal of Urology Online PRINCETON, N.J. --(BUSINESS WIRE)--Nov. 26, 2024-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights results
New Drug Application for UGN-102 accepted by US FDA ; PDUFA target action date set for June 13, 2025 JELMYTO ® achieved net product sales of $25.2 million in Q3 2024, compared to $20.9 million in Q3 2023 $254.2 million in cash, cash equivalents and marketable securities as of September 30, 2024
Fireside Chat on November 12, 2024 at 3:00 PM ET PRINCETON, N.J. --(BUSINESS WIRE)--Nov. 5, 2024-- UroGen Pharma Ltd. (Nasdaq:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that management will
Conference Call and Webcast Scheduled for Wednesday, November 6, 2024 , at 10:00AM ET PRINCETON, N.J. --(BUSINESS WIRE)--Oct. 30, 2024-- UroGen Pharma Ltd. (Nasdaq:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers,
The Kaplan-Meier Estimate of Duration of Response at 12 Months in Patients Who Achieved a Complete Response at Three Months was 82.3% Patients Receiving UGN-102 had a 79.6% Complete Response Rate at Three Months Side Effect Profile Consistent with Previous Clinical Trials of UGN-102 PRINCETON, N.J
PDUFA goal date set for June 13, 2025 UGN-102 would be the first FDA-approved medicine for LG-IR-NMIBC, if approved PRINCETON, N.J. --(BUSINESS WIRE)--Oct. 15, 2024-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat
Mr. Degnan has extensive experience in financial strategy, investor relations, SEC reporting, accounting and compliance PRINCETON, N.J. --(BUSINESS WIRE)--Oct. 9, 2024-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat
Anticipated advantages of UGN-103 include a shorter manufacturing process and a simpler reconstitution procedure PRINCETON, N.J. --(BUSINESS WIRE)--Oct. 2, 2024-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat
Once issued, this patent provides U.S. intellectual property coverage of UroGen’s RTGel ® technology with medac lyophilized mitomycin formulation, covering UGN-103 and UGN-104 development programs until December 2041 PRINCETON, N.J. --(BUSINESS WIRE)--Sep. 16, 2024-- UroGen Pharma Ltd.
